Atypical teratoid/rhabdoid tumoroids reveal subgroup-specific drug vulnerabilitiesIrene Paassen, Jarno Drost, Justin Williams et al.|Oncogene|2023Cited by 37
Trabectedin (ET-743, Yondelis™) is a substrate for P-glycoprotein, but only high expression of P-glycoprotein confers the multidrug resistance phenotypeJan H. Beumer, Olaf van Tellingen, Tessa Buckle et al.|Investigational New Drugs|2006Cited by 17
Disposition and toxicity of trabectedin (ET-743) in wild-type and mdr1 gene (P-gp) knock-out miceJan H. Beumer, Olaf van Tellingen, N. Franke et al.|Investigational New Drugs|2009Cited by 13
Gemcitabine therapeutically disrupts essential SIRT1-mediated p53 repression in atypical teratoid/rhabdoid tumorsDennis S. Metselaar, Esther Hulleman, N. Franke et al.|Cell Reports Medicine|2024Cited by 8
A cycling, progenitor-like cell population at the base of atypical teratoid rhabdoid tumor subtype differentiation trajectoriesEnrique Blanco-Carmona, Jarno Drost, Irene Paassen et al.|Neuro-Oncology|2025Cited by 2